OA12549A - Method of treating of demyelinating diseases or conditions. - Google Patents
Method of treating of demyelinating diseases or conditions. Download PDFInfo
- Publication number
- OA12549A OA12549A OA1200300199A OA1200300199A OA12549A OA 12549 A OA12549 A OA 12549A OA 1200300199 A OA1200300199 A OA 1200300199A OA 1200300199 A OA1200300199 A OA 1200300199A OA 12549 A OA12549 A OA 12549A
- Authority
- OA
- OAPI
- Prior art keywords
- hydrogen
- compound
- halogen
- formula
- duplicata
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26884601P | 2001-02-15 | 2001-02-15 | |
| GBGB0119435.6A GB0119435D0 (en) | 2001-02-15 | 2001-08-09 | Method of treating of demyelinating diseases or conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12549A true OA12549A (en) | 2006-06-05 |
Family
ID=23024747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200300199A OA12549A (en) | 2001-02-15 | 2002-02-14 | Method of treating of demyelinating diseases or conditions. |
Country Status (39)
| Country | Link |
|---|---|
| US (10) | US6967210B2 (sh) |
| EP (1) | EP1368031A2 (sh) |
| JP (3) | JP2004518711A (sh) |
| KR (3) | KR100951542B1 (sh) |
| CN (2) | CN1529598A (sh) |
| AP (1) | AP1749A (sh) |
| AR (1) | AR035750A1 (sh) |
| AU (3) | AU2002247200B9 (sh) |
| BR (1) | BR0207272A (sh) |
| CA (1) | CA2438712A1 (sh) |
| CO (1) | CO5390085A1 (sh) |
| CR (1) | CR7023A (sh) |
| CZ (1) | CZ20032172A3 (sh) |
| EA (2) | EA011319B1 (sh) |
| EC (1) | ECSP024218A (sh) |
| EE (1) | EE200300363A (sh) |
| GB (1) | GB0119435D0 (sh) |
| HK (1) | HK1080361B (sh) |
| HR (1) | HRP20030652A2 (sh) |
| HU (1) | HUP0303203A3 (sh) |
| IL (2) | IL157341A0 (sh) |
| MA (1) | MA26152A1 (sh) |
| ME (1) | MEP21208A (sh) |
| MX (1) | MXPA03006110A (sh) |
| MY (1) | MY157745A (sh) |
| NO (1) | NO20033622L (sh) |
| NZ (4) | NZ544720A (sh) |
| OA (1) | OA12549A (sh) |
| PA (1) | PA8540101A1 (sh) |
| PE (1) | PE20040175A1 (sh) |
| PL (1) | PL363638A1 (sh) |
| SG (1) | SG134170A1 (sh) |
| SK (1) | SK10392003A3 (sh) |
| TR (4) | TR200800693T2 (sh) |
| TW (1) | TWI325319B (sh) |
| UA (2) | UA80394C2 (sh) |
| WO (1) | WO2002064126A2 (sh) |
| YU (1) | YU62903A (sh) |
| ZA (1) | ZA200306124B (sh) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
| AU2003301184A1 (en) * | 2002-12-20 | 2004-07-22 | Dynogen Pharmaceuticals Inc | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS |
| JP2006515327A (ja) * | 2003-01-30 | 2006-05-25 | ダイノジェン ファーマシューティカルズ， インコーポレイテッド | ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法 |
| DE602004003172T2 (de) * | 2003-03-21 | 2007-09-27 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals |
| GT200500063A (es) * | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
| GB0510164D0 (en) * | 2005-04-28 | 2005-06-22 | Paradigm Therapeutics Ltd | Ion channel |
| FR2892021B1 (fr) * | 2005-10-19 | 2008-01-04 | Urogene | Traitement de l'incontinence urinaire d'effort et mixte |
| FR2892022B1 (fr) * | 2005-10-19 | 2008-01-04 | Urogene Sa | Traitement des symptomes de l'irritation de la vessie |
| US8420593B1 (en) * | 2006-06-16 | 2013-04-16 | Landon C. G. Miller | Compositions and methods for regulating membrane potential |
| DE102008044844B4 (de) * | 2008-08-28 | 2018-08-30 | Siemens Healthcare Gmbh | Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes |
| WO2011118364A1 (en) * | 2010-03-26 | 2011-09-29 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device |
| WO2012009204A1 (en) * | 2010-07-15 | 2012-01-19 | The Trustees Of Columbia University In The City Of New York | Methods for diagnosing and treating concussive disorders |
| WO2012103471A1 (en) * | 2011-01-28 | 2012-08-02 | Acorda Therapeutics, Inc. | Use of potassium channel blockers to treat cerebral palsy |
| TWI592156B (zh) * | 2011-10-04 | 2017-07-21 | 艾可達醫療公司 | 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法 |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| EP3727587A4 (en) | 2017-12-22 | 2022-02-23 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS) |
| US20240082184A1 (en) * | 2021-01-20 | 2024-03-14 | Rush University Medical Center | Improved treatment for globoid cell leukodsytrophy or krabbe disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| DE3852335T2 (de) * | 1987-04-24 | 1995-05-11 | Hoechst Roussel Pharma | N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel. |
| US4970218A (en) * | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| ES2068294T3 (es) * | 1989-08-02 | 1995-04-16 | Hoechst Roussel Pharma | 2,3-dihidro-1-(piridinilamino)-indoles, un procedimiento para su preparacion y su uso como medicamentos. |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| DE4325491A1 (de) * | 1993-07-29 | 1995-02-02 | Boehringer Ingelheim Kg | Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels |
| US5459274A (en) * | 1994-05-13 | 1995-10-17 | Hoechst-Roussel Pharmaceuticals Inc. | Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines |
| US5565475A (en) * | 1994-11-08 | 1996-10-15 | Muhlhauser; Mark A. | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives |
| EP0731108A1 (en) * | 1995-03-10 | 1996-09-11 | Boehringer Mannheim Gmbh | Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes |
| FR2754147B1 (fr) | 1996-10-03 | 2000-02-04 | Mbh Technologies Sa | Installation et procede pour le traitement de carcasses |
| AU730592B2 (en) * | 1998-01-29 | 2001-03-08 | Bristol-Myers Squibb Company | Phosphate derivatives of diaryl 1,3,4-oxadiazolone |
| WO2001004091A1 (en) * | 1999-07-09 | 2001-01-18 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2001
- 2001-08-09 GB GBGB0119435.6A patent/GB0119435D0/en not_active Ceased
-
2002
- 2002-02-14 EA EA200300882A patent/EA011319B1/ru not_active IP Right Cessation
- 2002-02-14 AP APAP/P/2003/002834A patent/AP1749A/en active
- 2002-02-14 EP EP02714974A patent/EP1368031A2/en not_active Withdrawn
- 2002-02-14 JP JP2002563920A patent/JP2004518711A/ja not_active Ceased
- 2002-02-14 CA CA002438712A patent/CA2438712A1/en not_active Abandoned
- 2002-02-14 AU AU2002247200A patent/AU2002247200B9/en not_active Ceased
- 2002-02-14 NZ NZ544720A patent/NZ544720A/en unknown
- 2002-02-14 TR TR2008/00693T patent/TR200800693T2/xx unknown
- 2002-02-14 HU HU0303203A patent/HUP0303203A3/hu unknown
- 2002-02-14 YU YU62903A patent/YU62903A/sh unknown
- 2002-02-14 CZ CZ20032172A patent/CZ20032172A3/cs unknown
- 2002-02-14 KR KR1020087031855A patent/KR100951542B1/ko not_active IP Right Cessation
- 2002-02-14 IL IL15734102A patent/IL157341A0/xx unknown
- 2002-02-14 EA EA200600896A patent/EA012409B1/ru not_active IP Right Cessation
- 2002-02-14 OA OA1200300199A patent/OA12549A/en unknown
- 2002-02-14 NZ NZ556697A patent/NZ556697A/en unknown
- 2002-02-14 NZ NZ527011A patent/NZ527011A/en unknown
- 2002-02-14 UA UA2003098376A patent/UA80394C2/uk unknown
- 2002-02-14 MX MXPA03006110A patent/MXPA03006110A/es active IP Right Grant
- 2002-02-14 TR TR2008/00691T patent/TR200800691T2/xx unknown
- 2002-02-14 TR TR2008/00692T patent/TR200800692T2/xx unknown
- 2002-02-14 BR BR0207272-6A patent/BR0207272A/pt not_active IP Right Cessation
- 2002-02-14 WO PCT/US2002/005501 patent/WO2002064126A2/en active Application Filing
- 2002-02-14 US US10/076,191 patent/US6967210B2/en not_active Expired - Lifetime
- 2002-02-14 CN CNA028048644A patent/CN1529598A/zh active Pending
- 2002-02-14 EE EEP200300363A patent/EE200300363A/xx unknown
- 2002-02-14 SG SG200505802-9A patent/SG134170A1/en unknown
- 2002-02-14 KR KR1020087031854A patent/KR20090005254A/ko not_active Application Discontinuation
- 2002-02-14 PL PL02363638A patent/PL363638A1/xx not_active Application Discontinuation
- 2002-02-14 ME MEP-212/08A patent/MEP21208A/xx unknown
- 2002-02-14 KR KR1020037010691A patent/KR100951540B1/ko not_active IP Right Cessation
- 2002-02-14 TR TR2003/01330T patent/TR200301330T2/xx unknown
- 2002-02-14 CN CNB2005100597348A patent/CN100522164C/zh not_active Expired - Fee Related
- 2002-02-14 NZ NZ539159A patent/NZ539159A/en unknown
- 2002-02-14 SK SK1039-2003A patent/SK10392003A3/sk unknown
- 2002-02-15 MY MYPI20020518A patent/MY157745A/en unknown
- 2002-02-15 EC EC2002004218A patent/ECSP024218A/es unknown
- 2002-02-15 CO CO02013025A patent/CO5390085A1/es not_active Application Discontinuation
- 2002-02-15 AR ARP020100540A patent/AR035750A1/es unknown
- 2002-02-15 TW TW091102861A patent/TWI325319B/zh not_active IP Right Cessation
- 2002-02-18 PA PA20028540101A patent/PA8540101A1/es unknown
- 2002-02-26 PE PE2002000159A patent/PE20040175A1/es not_active Application Discontinuation
-
2003
- 2003-07-11 MA MA27235A patent/MA26152A1/fr unknown
- 2003-07-16 CR CR7023A patent/CR7023A/es unknown
- 2003-08-07 ZA ZA200306124A patent/ZA200306124B/xx unknown
- 2003-08-11 IL IL157341A patent/IL157341A/en not_active IP Right Cessation
- 2003-08-13 HR HR20030652A patent/HRP20030652A2/hr not_active Application Discontinuation
- 2003-08-14 NO NO20033622A patent/NO20033622L/no not_active Application Discontinuation
-
2004
- 2004-02-03 US US10/770,656 patent/US20040157889A1/en not_active Abandoned
- 2004-02-03 US US10/770,655 patent/US20040157888A1/en not_active Abandoned
-
2005
- 2005-03-14 US US11/079,327 patent/US7230015B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/079,366 patent/US7179821B2/en not_active Expired - Lifetime
- 2005-09-27 US US11/236,145 patent/US7534803B2/en not_active Expired - Fee Related
-
2006
- 2006-01-05 HK HK06100186.8A patent/HK1080361B/zh not_active IP Right Cessation
- 2006-04-04 UA UAA200603708A patent/UA88773C2/ru unknown
-
2008
- 2008-03-13 AU AU2008201179A patent/AU2008201179B2/en not_active Ceased
-
2009
- 2009-04-06 JP JP2009091807A patent/JP2009185045A/ja not_active Abandoned
- 2009-04-29 US US12/420,381 patent/US20090270458A1/en not_active Abandoned
- 2009-04-29 US US12/420,390 patent/US20090281147A1/en not_active Abandoned
- 2009-04-29 US US12/420,407 patent/US20090209594A1/en not_active Abandoned
- 2009-04-29 US US12/420,416 patent/US20090209595A1/en not_active Abandoned
- 2009-11-19 AU AU2009238332A patent/AU2009238332A1/en not_active Abandoned
-
2010
- 2010-02-16 JP JP2010030929A patent/JP2010120958A/ja not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008201179B2 (en) | Method of treating of demyelinating diseases or conditions | |
| AU2002247200A1 (en) | Method of treating of demyelinating diseases or conditions | |
| US5547969A (en) | Method for the treatment of bradyphrenia in Parkinson's disease patients | |
| JP2001510157A (ja) | 末梢作用性抗掻痒オピエート | |
| KR20040030788A (ko) | 요실금 치료를 위한 아릴(또는 헤테로아릴)아졸릴카르비놀 유도체 | |
| JP2000515549A (ja) | 物質乱用を処置する方法 | |
| CA2028645A1 (en) | Use of arylalkylamides in the treatment of neurodegenerative diseases | |
| US5834497A (en) | Use of felodipine to treat cerebral dysfunction due to solvent exposure | |
| JP2000515865A (ja) | 過剰攻撃を処置する方法 |